注射用尤瑞克林治疗急性进展性脑梗死患者64例的疗效观察

Curative effect observation of urinary kallidinogenase for injection in the treatment of 64 cases of acute progressive cerebral infarction

目的观察注射用尤瑞克林治疗急性进展性脑梗死的临床疗效及不良反应。方法急性进展性脑梗死住院患者128例,随机分为对照组和观察组,对照组(64例)应用常规治疗方案,观察组(64例)在常规治疗方案基础上加用注射用尤瑞克林0.15 PNA,1次/d,疗程14 d,观察两组在治疗前及治疗后14 d的神经功能缺损程度(NIHSS)评分、日常生活活动能力(ADL)评分、临床疗效及不良反应发生情况。结果两组患者治疗后14 d NIHSS、ADL评分均较治疗前明显改善(P<0.05);观察组显著高于对照组(P<0.05);临床有效率达81.3%,显著高于对照组68.8%(P<0.05),两组均未发现严重不良反应。结论注射用尤瑞克林治疗急性进展性脑梗死有效并且相对安全。

Objective To observe the clinical effect and adverse reactions of urinary kallidinogenase for injection in the treatment of acute progressive cerebral infarction. Methods A total of 128 patients with acute progressive cerebral infarction were randomly divided into control group and observation group. The control group （n=64） received conventional treatment method, while the observation group （n=64） was treated by additional 0.15 PNA urinary kallidinogenase for injection by ltime/d for 14 d. National institutes of health stroke scale （NIHSS）, activities of daily living （ADL） score, clinical effects, and adverse reactions were observed in the two groups before and after 14 d of treatment. Results The scores of NIHSS and ADL were all improved after 14 d of treatment in the two groups （P〈0.05）, and those in the observation group were higher than in the control group （P〈0.05）. The clinical effective rate of the observation group was 81.3%, which was obviously higher than 68.8% of the control group （P〈0.05）. No severe adverse reactions were found in the two groups. Conclusion Treatment of acute progressive cerebral infarction by urinary kallidinogenase for injection is effective and relatively safe.